Literature DB >> 10534968

Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life.

R Aparasu1, R A McCoy, C Weber, D Mair, T V Parasuraman.   

Abstract

There is very little information in the medical literature regarding opioid-induced emesis and its relationship to patient outcomes. Two-hundred and six nonsurgical patients in a 400-bed teaching hospital with minimal known risks of disease-associated emesis were interviewed to examine emesis and associated outcomes following the administration of opioids for acute pain management. The mean age, weight, and height of the study group were 54.4 (+/- 19.6) years, 175.8 (+/- 45.7) pounds, and 67.1 (+/- 4.4) inches, respectively. Seventy-three (35.4%) patients experienced nausea; 28 (13.6%) patients vomited; and 15 (7.3%) patients retched following the opioid therapy. These symptoms were mild and discomforting for relatively short periods of time. The patients' ability to concentrate and eat was affected by the incidence of nausea/vomiting. The intensity, duration, and severity of nausea were positively associated with the magnitude of the functional limitations. The symptoms also influenced patients' ratings of various hospital satisfaction measures. In conclusion, emesis due to opioids represents a notable burden on nonsurgical patients. Successful therapies that prevent opioid-induced emesis are likely to positively influence patient outcomes by reducing adverse effects, improving functional outcomes, and enhancing quality of life.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534968     DOI: 10.1016/s0885-3924(99)00085-8

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  13 in total

Review 1.  Responsible prescribing of opioids for the management of chronic pain.

Authors:  Bruce Nicholson
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Effect of Prophylactic Anti-emetics on Opioid-induced Nausea and Vomiting: A Retrospective Observational Cohort Study.

Authors:  Tomoki Tamura; Keita Kawakado; G O Makimoto; Masamoto Nakanishi; Shoichi Kuyama
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

3.  Pain Management and Symptom-Oriented Drug Therapy in Palliative Care.

Authors:  Carsten Klein; Ute Lang; Johannes Bükki; Reinhard Sittl; Christoph Ostgathe
Journal:  Breast Care (Basel)       Date:  2011-02-22       Impact factor: 2.860

Review 4.  Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain.

Authors:  Lieven Annemans
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

5.  Opioid utilization patterns among medicare patients with diabetic peripheral neuropathy.

Authors:  Jacqueline Pesa; Roxanne Meyer; Tiffany P Quock; Stacy K Rattana; Samir H Mody
Journal:  Am Health Drug Benefits       Date:  2013-05

6.  Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study.

Authors:  Rok Seon Choung; G Richard Locke; Alan R Zinsmeister; Cathy D Schleck; Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2009-04-14       Impact factor: 10.864

7.  Tapentadol immediate release: a new treatment option for acute pain management.

Authors:  Marc Afilalo; Jens-Ulrich Stegmann; David Upmalis
Journal:  J Pain Res       Date:  2010-02-08       Impact factor: 3.133

8.  Experience and Management of the Adverse Effects of Analgesics After Surgery: A Pediatric Patient Perspective.

Authors:  Mandy M J Li; Cynthia L Larche; Kelsey Vickers; Marie Vigouroux; Pablo M Ingelmo; Richard Hovey; Catherine E Ferland
Journal:  J Patient Exp       Date:  2022-04-07

9.  Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats.

Authors:  M Guarnieri; C Brayton; R Sarabia-Estrada; B Tyler; P McKnight; L DeTolla
Journal:  J Vet Med       Date:  2017-04-09

10.  Exploring binding properties of agonists interacting with a δ-opioid receptor.

Authors:  Francesca Collu; Matteo Ceccarelli; Paolo Ruggerone
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.